Denmark

SANYOU BIO

Sanyou Biopharmaceuticals is a global leader in high-tech biotechnology, specialized in innovative biologics R&D and services. Sanyou integrated 4C model – “differentiated CRO, integrated CDO, innovative CPO and characteristic CRS – effectively bridges the gap between research and manufacturing, streamlining the discovery of groundbreaking biologics worldwide.

Their products include:

Immune Checkpoint Proteins – Proteins expressed in immune cells and can maintain immune homeostasis. Their abnormal expression and functional imbalance lead to various diseases, such as tumors and autoimmunity. In recent years, the successive marketing of antibody drugs developed for immune checkpoints, has opened the door to immunotherapy.
Antibody-drug conjugates (ADCs) – ADCs refer to a new class of biotherapeutic drugs manufactured by conjugating monoclonal antibodies and small molecule cytotoxic drugs by linkers. Compared with traditional cytotoxic drugs, ADC has the advantages of strong targeting and less toxic side effects.
Virus-Like Particles (VLPs) – VLPs are derived from viral capsid proteins and represent small, nanoscale viral particles. However, they do not possess viral infectivity. Using the VLP technology platform, it is possible to showcase membrane proteins with their natural conformation on the surface of these virus-like particles. This capability makes them valuable for applications in immunization and antibody screening.
Antibodies – Include Reference antibodies, Bispecific and ADC reference antibodies, Enzyme labeled antibodies, Flow Cytometry antibodies etc.
Proteins – Include Cytokines, Immunomodulatory proteins, Fc receptors, Tumor Associated Antigens, ADC Associated Antigens, Bispecific Associated Antigens, VLPs etc.
Cell Lines – Mainly includes Over Expression Cell Lines, Reporter gene cell lines.